Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Oveporexton is an oral orexin receptor 2 (OX2R)-selective agonist indicated for narcolepsy type 1 in adults, restoring deficient orexin signaling to promote wakefulness and reduce cataplexy and other REM-sleep-related symptoms. NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other REM-sleep-related symptoms.
- Mechanism
- Curator reviewed
Pharmacologically active on Orexin receptor type 2
- Primary indication
- Oveporexton is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.Curator reviewed · 1 structured indication
- Formula / weight
- C23H25F5N2O4S · 520.52 g/mol (avg)
- Code names
- TAK-861
Resolves to
KVMGAIOTUIGROS-AZUAARDMSA-NSMILESCCS(=O)(=O)N[C@@H]1[C@H](CC2=CC=CC(=C2F)C2=CC(F)=CC(F)=C2)N(CC1(F)F)C(=O)C(C)(C)OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Oveporexton, and which of those have an active Phase 3 trial?